# US 2015/0030621 A1 · Baculovirus-based vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0030621 A1
- Document ID: US20150030621A1
- Status: Published application
- Kind: A1
- Application number: 14/447,341
- Filed: 2014-07-30
- Published: 2015-01-29
- Earliest claimed: 2008-01-09
- Assignees: Konkuk University Industrial Cooperation Corp.; KR Biotech Co., Ltd.
- Applicants: Konkuk University Industrial Cooperation Corp.; KR Biotech Co., Ltd.
- Inventors: Young-Bong KIM; Hee Jung Lee; Nuri Park; Yu-Kyoung Oh
- Web page: https://patentgrep.com/patent/US20150030621A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 2039/5256: {expressing foreign proteins}
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- C12N 2710/14145: Special targeting system for viral vectors
- C12N 2710/14171: Demonstrated in vivo effect
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2810/6054: Retroviridae
- C12N 2830/60: from viruses
- C12N 2830/85: mammalian
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method for inducing an immune response against a specific antigen in a mammalian subject in need thereof, comprising:
(a) transfecting into a insect cell a recombinant bacmid comprising: (i) a nucleotide sequence encoding an envelope protein of an endogenous retrovirus; (ii) a first promoter that is operable in insect cells and is operatively linked to (i); (iii) a nucleotide sequence encoding an antigen protein; and (iv) a second promoter that is derived from a mammalian genome or virus and is operatively linked to (iii);
(b) obtaining a recombinant baculovirus which is produced from the insect cell; and
(c) administering a pharmaceutically effective amount of the recombinant baculovirus of (b) to the mammalian subject.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the antigen comprises a viral antigen, a bacterial antigen, a parasitic antigen or a cancer antigen.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the antigen comprises the viral antigen selected from the group consisting of HPV (human papillomavirus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, rotavirus antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, avian influenza virus antigen, hog cholera virus antigen, foot-and-mouth disease virus antigen and Newcastle disease virus antigen.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the antigen is HPV antigen, and the method is a method for preventing or treating a HPV infection-induced cancer.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the antigen comprises HPV L1, L2, E6 or E7 protein.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the HPV antigen protein is derived from HPV selected from the group consisting of HPV type 1, 2, 3a, 4, 5, 6b, 7, 8, 9, 10, 11a, 12, 13, 16 and 18.

### Claim 26 (depends on 20)

The method according to claim 20, wherein the endogenous retrovirus envelope protein is a HERV (human endogenous retrovirus) envelope protein.

### Claim 27 (depends on 26)

The method according to claim 26, wherein a nucleotide sequence encoding the HERV envelope protein comprises a nucleotide sequence encoding an amino acid sequence of SEQ ID NO:2.

### Claim 28 (depends on 20)

The method according to claim 20, wherein the promoter operable in insect cells comprises IE-1 promoter, IE-2 promoter, p35 promoter, p10 promoter, gp64 promoter or polyhedrin promoter.

### Claim 29 (depends on 20)

The method according to claim 20, wherein the second promoter comprises U6 promoter, H1 promoter, CMV (cytomegalo virus) promoter, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, HSV tk promoter, RSV promoter, human elongation factor 1α (hEF1α) promoter, methallothionein promoter, β-actin promoter, human IL-2 gene promoter, human IFN gene promoter, human IL-4 gene promoter, human lymphotoxin gene promoter, human GM-CSF gene promoter, TERT promoter, PSA promoter, PSMA promoter, CEA promoter, E2F promoter, AFP promoter or albumin promoter.
